Gynecologic oncology · 2025
Utilization and outcomes of fertility-sparing ovarian cystectomy for stage I malignant ovarian germ cell tumors.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Ludmir Delanie, Huang Yongmei, Xu Xiao, Dioun Shayan, de Meritens Alexander Buckley, Randall Thomas, Pua Tarah, St Clair Caryn M, Hou June Y, Matsuo Koji, Hershman Dawn L, Wright Jason D
Аннотация
OBJECTIVE: Treatment for malignant ovarian germ cell tumors {MOGCTs) in women desiring fertility preservation is typically unilateral salpingo-oophorectomy (USO). While small studies have examined cystectomy for immature teratomas, larger-scale data are limited. We evaluated use and survival outcomes of cystectomy versus USO for stage I MOGCTs.
METHODS: Using the National Cancer Database, we identified women aged 18-49 with stage I MOGCTs who underwent cystectomy or USO from 2004 to 2022. Log-linear regression identified factors associated with cystectomy. Propensity score inverse probability of treatment weighting (IPTW) for average treatment effect on the treated (IPTW-ATT) was applied to estimate the association of cystectomy versus USO with survival using weighted Cox proportional hazards models and Kaplan-Meier curves.
RESULTS: Among 1345 patients, 1194 (88.8 %) underwent USO and 151 (11.2 %) cystectomy. Cystectomy use declined from 18.4 % (2004) to 9.4 % (2022) (P < 0.0001, APC = -5.5 %). Cystectomy was more common in mixed germ cell tumors and at community cancer programs. Patients who underwent cystectomy were less likely to receive lymphadenectomy (21.4 % vs. 35.3 %, SMD = 0.32), while adjuvant chemotherapy use was similar between groups. Adjusted 2-year survival was 99.7 % (USO) vs. 100.0 % (cystectomy), and 5-year survival was 98.7 % (USO) vs. 98.4 % (cystectomy). Adjusted hazard ratio for overall mortality was 0.70 (95 %CI: 0.21-2.33) for cystectomy versus USO. Stratified analyses by histology and age showed no survival differences.
CONCLUSION: Cystectomy use for stage I MOGCT has declined over time. Among patients who underwent cystectomy, estimated overall survival did not differ significantly from that expected of USO, including across histologic subtypes and age.
METHODS: Using the National Cancer Database, we identified women aged 18-49 with stage I MOGCTs who underwent cystectomy or USO from 2004 to 2022. Log-linear regression identified factors associated with cystectomy. Propensity score inverse probability of treatment weighting (IPTW) for average treatment effect on the treated (IPTW-ATT) was applied to estimate the association of cystectomy versus USO with survival using weighted Cox proportional hazards models and Kaplan-Meier curves.
RESULTS: Among 1345 patients, 1194 (88.8 %) underwent USO and 151 (11.2 %) cystectomy. Cystectomy use declined from 18.4 % (2004) to 9.4 % (2022) (P < 0.0001, APC = -5.5 %). Cystectomy was more common in mixed germ cell tumors and at community cancer programs. Patients who underwent cystectomy were less likely to receive lymphadenectomy (21.4 % vs. 35.3 %, SMD = 0.32), while adjuvant chemotherapy use was similar between groups. Adjusted 2-year survival was 99.7 % (USO) vs. 100.0 % (cystectomy), and 5-year survival was 98.7 % (USO) vs. 98.4 % (cystectomy). Adjusted hazard ratio for overall mortality was 0.70 (95 %CI: 0.21-2.33) for cystectomy versus USO. Stratified analyses by histology and age showed no survival differences.
CONCLUSION: Cystectomy use for stage I MOGCT has declined over time. Among patients who underwent cystectomy, estimated overall survival did not differ significantly from that expected of USO, including across histologic subtypes and age.